semaglutide and fatty liver Once-Weekly Subcutaneous Improves Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study Novo Nordisk will file semaglutide

Because of its selective stimulation of growth hormone release, it helps preserve cognitive function

GLP-1 drugs (glucagon-like peptide-1 receptor agonists) are medications developed to treat both type 2 diabetes and obesity by correcting hormonal imbalance - stimulating insulin release and suppressing excess glucagon -to bring blood sugar back under control

By default, that means its detoxifying the liver, which helps stave off conditions like fatty liver disease

VESPER-3 VESPER-3 was a 64-week placebo-controlled trial that assessed the efficacy and safety of monthly berobenatide in adults with obesity or overweight with hypertension and/or dyslipidemia